fluconazole
Trade name: diflucan
Approved
Jan 29, 1990
Fluconazole, a synthetic antifungal agent of the imidazole class, is used to treat vaginal candidiasis. It inhibits the fungal lanosterol 14 alpha-demethylase which thereby prevents the formation of ergosterol which is an essential component in the fungal cell membrane. Indicated for the treatment of fungal infections. — NCATS
Clinical trial activity
219 trials · 200 clinical orgs · 34 marketing orgs
Earliest trial started Sep 1, 1991 (NCT00004808)
Timeline
1990s
2000s
- May 1, 2003
Ranbaxy — Marketing Organization
- May 9, 2003
Pliva — Marketing Organization
- Sep 25, 2003
Gedeon Richter Ltd. — Marketing Organization
- Oct 30, 2003
Hospira — Marketing Organization
- Jul 29, 2004
Ani Pharmaceuticals — Marketing Organization
- Jul 29, 2004
Apotex — Marketing Organization
- Jul 29, 2004
Dr. Reddy's Laboratories — Marketing Organization
- Jul 29, 2004
Fresenius — Marketing Organization
- Jul 29, 2004
Mylan — Marketing Organization
- Jul 29, 2004
West-Ward Pharmaceutical — Marketing Organization
- Jul 29, 2004
Roxane Laboratories — Marketing Organization
- Jul 29, 2004
Sun Pharmaceuticals — Marketing Organization
- Jul 29, 2004
Taro Pharmaceuticals — Marketing Organization
- Jul 29, 2004
Teva — Marketing Organization
- Jul 29, 2004
Chartwell Pharmaceuticals — Marketing Organization
- Jul 29, 2004
Boehringer Ingelheim — Marketing Organization
- Jul 29, 2004
Baxter — Marketing Organization
- Jul 29, 2004
PHARMOBEDIENT — Marketing Organization
- Aug 23, 2005
Hikma — Marketing Organization
- Sep 28, 2005
Unique Pharmaceuticals Ltd, India — Marketing Organization
- Sep 28, 2005
THINQ Pharma CRO Ltd. — Marketing Organization
- Jan 25, 2006
Glenmark Pharmaceuticals — Marketing Organization
- Oct 7, 2008
Aurobindo Pharma — Marketing Organization
- Jul 30, 2009
Inforlife — Marketing Organization
2010s
- May 26, 2010
Baxalta — Marketing Organization
- May 26, 2010
Renaissance Pharma — Marketing Organization
- May 26, 2010
Woodward — Marketing Organization
- Mar 7, 2011
Harris Laboratories, Incorporated — Marketing Organization
- Feb 16, 2017
Zydus Discovery DMCC — Marketing Organization
2020s
- Sep 21, 2023
Hainan Poly Pharm — Marketing Organization
- Sep 21, 2023
ZHEJIANG POLY PHARM — Marketing Organization
- Oct 20, 2023
Lupin — Marketing Organization
- Jan 8, 2026
FDC — Marketing Organization
Indications
Approved for
Studied for
- Abdominal Injuries · Phase 2
- Acquired Immunodeficiency Syndrome · Phase 4
- AIDS-Related Opportunistic Infections · Phase 3
- Alzheimer Disease · Phase 1
- Antibiotic Prophylaxis · Phase 3
- Appendicitis · Phase 3
- Arrhythmias, Cardiac · Phase 3
- Arteries · Phase 4
- Aspergillosis · Phase 3
- Aspergillus · Phase 3
- Bacterial Infections · Phase 3
- Bacterial Infections and Mycoses · Phase 4
- Biological Availability · Phase 1
- Blastomycosis · Phase 2
- Burns · Phase 4
- Candidemia · Phase 3
- Candidiasis · Phase 4
- Candidiasis, Invasive · Phase 3
- Candidiasis, Oral · Phase 4
- Candidiasis, Vulvovaginal · Phase 4
- Cardiovascular Diseases · Phase 1
- Central Nervous System Fungal Infections · Phase 4
- Coccidioidomycosis · Phase 4
- Conjunctivitis · Phase 4
- Crohn Disease · Phase 3
- Cryptococcosis · Phase 4
- Cryptococcus · Phase 3
- Cryptococcus neoformans · Phase 4
- Cystectomy · Phase 4
- Dermatitis, Atopic · Phase 1
- Diabetes Mellitus · Phase 3
- Diabetes Mellitus, Type 2 · Phase 1
- Drug Interactions · Phase 1
- Duodenal Ulcer · Phase 3
- Dyslipidemias · Phase 1
- Endometriosis · Phase 1
- Fluconazole · Phase 4
- Fungemia · Phase 4
- Gastroesophageal Reflux · Phase 1
- Graft vs Host Disease · Phase 1
- Head and Neck Neoplasms · Phase 2/Phase 3
- Health · Phase 1
- Healthy Volunteers · Phase 4
- Heart Arrest · Phase 1
- Hematopoietic Stem Cell Transplantation · Phase 2
- Histoplasmosis · Phase 2
- HIV · Phase 3
- HIV Infections · Phase 4
- Hypercalciuria · Phase 3
- Hypercholesterolemia · Phase 1
- Hyperlipidemias · Phase 2
- Hypoparathyroidism · Phase 2
- Hypothermia · Phase 3
- Infant, Very Low Birth Weight · Phase 2
- Infections · Phase 3
- Inflammatory Bowel Diseases · Phase 3
- Intestinal Diseases · Phase 3
- Invasive Fungal Infections · Phase 4
- Leishmaniasis, Cutaneous · Phase 3
- Leukemia · Phase 3
- Leukemia, B-Cell · Phase 1
- Leukemia, Monocytic, Acute · Phase 3
- Leukemia, Myeloid · Phase 3
- Leukemia, Myeloid, Acute · Phase 3
- Leukemia, Myelomonocytic, Acute · Phase 3
- Leukopenia · Phase 3
- Liver Transplantation · Phase 3
- Lung Diseases, Fungal · Phase 4
- Lymphoma · Phase 3
- Lymphoma, B-Cell, Marginal Zone · Phase 1
- Lymphoma, Large B-Cell, Diffuse · Phase 1
- Lymphoma, Mantle-Cell · Phase 1
- Meningitis · Phase 2
- Meningitis, Cryptococcal · Phase 4
- Meningoencephalitis · Phase 2
- Metabolic Detoxication, Phase I · Phase 1
- Mycobacterium avium-intracellulare Infection · Phase 3
- Mycoses · Phase 4
- Mycosis Fungoides · Phase 3
- Neoplasms · Phase 3
- Nephrocalcinosis · Phase 3
- Nephrolithiasis · Phase 3
- Neutropenia · Phase 3
- Non-alcoholic Fatty Liver Disease · Phase 1
- Obesity · Phase 4
- Osteoarthritis, Knee · Phase 3
- Pain · Phase 1
- Pharmacology, Clinical · Phase 1
- Pneumocystis · Phase 3
- Pneumonia, Ventilator-Associated · Phase 3
- Prostatic Neoplasms · Phase 1
- Pulmonary Disease, Chronic Obstructive · Phase 1
- Respiratory Syncytial Virus Infections · Phase 1
- Sepsis · Phase 4
- Sexually Transmitted Diseases · Phase 3
- Sporotrichosis · Phase 2
- Stem Cell Transplantation · Phase 1
- Therapeutic Equivalency · Phase 1
- Tinea Capitis · Phase 3
- Tinea Versicolor · Phase 4
- Urinary Bladder, Overactive · Phase 1
- Vaginal Discharge · Phase 3
- Vaginitis · Phase 3
- Vaginosis, Bacterial · Phase 3
- Vulvovaginitis · Phase 2
Mechanism of action
- Cytochrome P450 51INHIBITOR
ERG11 inhibitor
Approval history
- approvedPriority reviewJan 29, 1990
Chemistry & pharmacology
SMILES
OC(CN1C=NC=N1)(CN2C=NC=N2)C3=CC=C(F)C=C3F- Mol. weight
- 306.2708 g/mol
- Lipinski Ro5
- Pass
- Rule of 3
- No
- Chirality
- Achiral Molecule
- Inorganic
- No
- Polymer
- No
- Delivery
- Oral, Parenteral
- Availability
- Prescription Only
Oral
Yes
Parenteral
Yes
Topical
No
Sources
- WikipediaFluconazole ↗
- NCATS8VZV102JFY ↗
- ChEMBLCHEMBL106 ↗
Also known as
- 2-(2,4-difluorophenyl)-1,3-di(1h-1,2,4-triazol-1-yl)propan-2-ol
- 2-(2,4-difluorophenyl)-1,3-di(1h-1,2,4-triazol-1-yl)propan-2-ol
- 2,4-difluoro-alpha,alpha-bis(1h-1,2,4-triazol-1-ylmethyl)benzyl alcohol
- 2,4-difluoro-alpha,alpha-bis(1h-1,2,4-triazol-1-ylmethyl)benzyl alcohol
- biozole
- biozole
- canesten oral
- diflucan
- diflucan
- diflucan
- diflucan
- diflucan in sodium chloride
- diflucan one
- difluconazole
- elazor
- elazor
- fluconazol
- fluconazol
- fluconazole
- fluconazole
- fluconazole
- fluconazole
- fluconazole
- fluconazole
- fluconazole
- fluconazole
- fluconazole
- fluconazole
- fluconazole
- fluconazole in sodium chloride
- fluconazolum
- fluconazolum
- flunazol
- triflucan
- triflucan
- triflucan
- uk-49858
- uk-49858
Clinical trials
| NCT ID | Phase | Start date | Sponsor(s) |
|---|---|---|---|
| NCT07295314 | Early Phase 1 (Phase 1) | Jan 31, 2026 | University of Amsterdam, ZonMw: The Netherlands Organisation for Health Research and Development |
| NCT07044765 | Phase 1 | Aug 31, 2025 | Aju Pharm |
| NCT07034781 | Phase 1 | Aug 31, 2025 | Aju Pharm |
| NCT07033962 | N/A | Jun 30, 2025 | Assiut University |
| NCT06933459 | Phase 1 | May 24, 2025 | Aju Pharm |
| NCT06954766 | Phase 2 | May 12, 2025 | Chong Kun Dang Pharmaceutical |
| NCT06988670 | Phase 2 | May 5, 2025 | Extend Biosciences |
| NCT06916130 | Phase 1 | Apr 21, 2025 | Addpharma Inc. |
| NCT06931327 | Phase 1 | Mar 29, 2025 | Aju Pharm |
| NCT06922344 | Phase 4 | Mar 1, 2025 | Khyber Medical University Peshawer |
| NCT06847464 | Phase 1 | Jan 27, 2025 | Enanta Pharmaceuticals |
| NCT06771063 | Phase 2 | Jan 13, 2025 | Cisen Pharmaceutical |
| NCT06274554 | Phase 3 | Oct 4, 2024 | Cornell University, The Leona M. and Harry B. Helmsley Charitable Trust |
| NCT07311759 | Phase 3 | Aug 17, 2024 | Cairo University |
| NCT06770530 | Phase 4 | Jun 24, 2024 | University of Copenhagen |
| NCT06345794 | Phase 1 | Apr 3, 2024 | Eli Lilly |
| NCT06173596 | Phase 1 | Dec 21, 2023 | Alexion |
| NCT06822166 | Phase 1 | Dec 4, 2023 | Fosun, Shandong Province Qianfoshan Hospital |
| NCT06616168 | Phase 1 | Sep 1, 2023 | Lviv National Medical University |
| NCT05881187 | N/A | Jun 15, 2023 | Sohag University |
Organizations
Research & Development (200)
| Organization | Org type | Trials | As lead sponsor | Phases | Earliest year |
|---|---|---|---|---|---|
| Pfizer | For profit | 38 | 34 | 4 | 1998 |
| National Institute of Allergy and Infectious Diseases (NIAID) | Government | 19 | 15 | 5 | 1991 |
| Chong Kun Dang Pharmaceutical | For profit | 7 | 7 | 2 | 2019 |
| Hengrui Therapeutics, Inc. | For profit | 6 | 6 | 2 | 2019 |
| National Cancer Institute (NCI) | Government | 5 | 3 | 1 | 1998 |
| Scynexis, Inc. | For profit | 5 | 5 | 2 | 2014 |
| University of Minnesota | Academic/Hospital | 5 | 3 | 3 | 2001 |
| Aju Pharm | For profit | 4 | 4 | 1 | 2025 |
| Astellas | For profit | 4 | 3 | 2 | 2003 |
| Boehringer Ingelheim | For profit | 4 | 4 | 2 | 2001 |
| Chonbuk National University | Academic/Hospital | 4 | 0 | 1 | 2019 |
| Cidara Therapeutics | For profit | 4 | 4 | 2 | 2016 |
| Duke University | Academic/Hospital | 4 | 3 | 3 | 2001 |
| University of Washington | Academic/Hospital | 4 | 3 | 3 | 1998 |
| Bristol-Myers Squibb | For profit | 3 | 2 | 1 | 2009 |
| Eli Lilly | For profit | 3 | 3 | 1 | 2013 |
| Enanta Pharmaceuticals | For profit | 3 | 3 | 1 | 2018 |
| National Heart, Lung, and Blood Institute (NHLBI) | Government | 3 | 1 | 3 | 2001 |
| National Institutes of Health (NIH) | Government | 3 | 1 | 2 | 2008 |
| Radboud University | Academic/Hospital | 3 | 2 | 2 | 2006 |
Marketing (50)
| Organization | Org type | Relationship | Date |
|---|---|---|---|
| Ani Pharmaceuticals | For profit | MKTG | Jul 29, 2004 |
| Ani Pharmaceuticals | For profit | SYN | Jul 29, 2004 |
| Apotex | For profit | MKTG | Jul 29, 2004 |
| Aurobindo Pharma | For profit | MKTG | Oct 7, 2008 |
| Aurobindo Pharma | For profit | SYN | Sep 18, 2009 |
| Baxalta | For profit | MKTG | May 26, 2010 |
| Baxalta | For profit | SYN | Jul 29, 2004 |
| Baxter | For profit | MKTG | Jul 29, 2004 |
| Boehringer Ingelheim | For profit | MKTG | Jul 29, 2004 |
| Chartwell Pharmaceuticals | For profit | MKTG | Jul 29, 2004 |
| Dr. Reddy's Laboratories | For profit | MKTG | Jul 29, 2004 |
| Dr. Reddy's Laboratories | For profit | SYN | Jul 29, 2004 |
| FDC | For profit | MKTG | Jan 8, 2026 |
| Fresenius | For profit | MKTG | Jul 29, 2004 |
| Gedeon Richter Ltd. | For profit | MKTG | Sep 25, 2003 |
| Glenmark Pharmaceuticals | For profit | MKTG | Jan 25, 2006 |
| Glenmark Pharmaceuticals | For profit | SYN | Jan 25, 2006 |
| Hainan Poly Pharm | For profit | MKTG | Sep 21, 2023 |
| Hainan Poly Pharm | For profit | SYN | Sep 21, 2023 |
| Harris Laboratories, Incorporated | For profit | MKTG | Mar 7, 2011 |
| Hikma | For profit | MKTG | Aug 23, 2005 |
| Hikma | For profit | SYN | Jul 29, 2004 |
| Hikma | For profit | SYN | Jul 29, 2004 |
| Hospira | For profit | MKTG | Oct 30, 2003 |
| Inforlife | For profit | MKTG | Jul 30, 2009 |
| Lupin | For profit | MKTG | Oct 20, 2023 |
| Lupin | For profit | SYN | Oct 20, 2023 |
| Mylan | For profit | MKTG | Jul 29, 2004 |
| Mylan | For profit | SYN | Mar 25, 2005 |
| Mylan | For profit | SYN | Apr 10, 2003 |
| PHARMOBEDIENT | For profit | MKTG | Jul 29, 2004 |
| Pfizer | For profit | NDA | Jan 29, 1990 |
| Pliva | For profit | MKTG | May 9, 2003 |
| Ranbaxy | For profit | MKTG | May 1, 2003 |
| Renaissance Pharma | For profit | MKTG | May 26, 2010 |
| Roxane Laboratories | For profit | MKTG | Jul 29, 2004 |
| Sun Pharmaceuticals | For profit | MKTG | Jul 29, 2004 |
| THINQ Pharma CRO Ltd. | For profit | MKTG | Sep 28, 2005 |
| Taro Pharmaceuticals | For profit | MKTG | Jul 29, 2004 |
| Taro Pharmaceuticals | For profit | SYN | Dec 18, 2006 |
| Teva | For profit | SYN | Jul 29, 2004 |
| Teva | For profit | SYN | Jul 29, 2004 |
| Teva | For profit | MKTG | Jul 29, 2004 |
| Teva | For profit | SYN | Jan 13, 2005 |
| Unique Pharmaceuticals Ltd, India | For profit | MKTG | Sep 28, 2005 |
| Unique Pharmaceuticals Ltd, India | For profit | SYN | Sep 28, 2005 |
| West-Ward Pharmaceutical | For profit | MKTG | Jul 29, 2004 |
| Woodward | For profit | MKTG | May 26, 2010 |
| ZHEJIANG POLY PHARM | For profit | MKTG | Sep 21, 2023 |
| Zydus Discovery DMCC | For profit | MKTG | Feb 16, 2017 |